This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Matthew Greving, PhD
V.P. Technology & Co-Founder at RubrYc Therapeutics


Dr. Greving has a passion and an awarded record for innovation in computation and laboratory integration. At RubrYc, he leads development of a unique machine learning backed epitope-selective antibody discovery platform for challenging targets. Dr. Greving founded his first company 20 years ago that developed software to deliver legacy mainframe data and algorithms to modern systems. Dr. Greving received a Ph.D. in Biochemistry in 2010. His thesis research helped establish the “Immunosignature” technology. Dr. Greving completed his metabolomics post-doctoral research at Scripps Research. Subsequently, Dr. Greving founded Nextval that developed a high-throughput mass spectrometry screening technology. These developments resulted in two prestigious awards: Society for Lab Automation and Screening (SLAS) 2012 "Innovation of the Year", and R&D Magazine's 2013 “Oscar of Innovation". After Nextval, Dr. Greving joined HealthTell to commercialize the Immunosignature diagnostic. He then utilized insight gained from HealthTell's library platform along with molecular simulation and machine learning to build RubrYc's epitope-selective antibody discovery platform.

Agenda Sessions

  • Epitope-Selective Antibody Discovery Enabled by Machine Learning